LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/People In The News/Tony Recupero New CCO at SI-BONE
People In The News

Tony Recupero New CCO at SI-BONE

July 27, 2016 2 min read Premium comments

Advertisement

Tony Recupero New CCO at SI-BONE
Tony Recupero

Tony Recupero, former advisor to NuVasive, Inc., LDR, Invuity, Inc. and Ortho Kinematics, Inc., among others, on their sales and go-to-market strategies, is the new Chief Commercial Officer at SI-BONE, Inc.

According to the July 5, 2016 news release, “Recupero brings extensive knowledge of commercialization strategies, developed through a career including more than 30 years in sales, marketing and executive leadership roles in the medical device and diagnostics industry.”

“Recupero was previously President of Catalyst Performance Advisors, LLC a consulting firm that developed and implemented comprehensive commercialization strategies for medical device and diagnostic clients. Recupero advised clients including NuVasive, LDR, Invuity and OrthoKinematics, among others, on their sales and go-to-market strategies. Prior to Catalyst, Recupero was President and CEO of Baxano, Inc., a medical technology company that developed and sold novel product and procedure solutions to treat lumbar spinal stenosis. During his tenure at Baxano, he grew revenue rapidly to over $9 million while executing a merger with Trans1 to form Baxano Surgical, Inc. Recupero was also previously Vice President of Sales at Kyphon, Inc. where he developed and implemented the company’s sales and marketing strategy, taking the company from pre-commercialization to over $213 million in revenue in five years. At Kyphon, Recupero built a direct sales organization of 225 sales consultants and developed a field based health care specialist education program that is now the industry standard for medical device organizations and established the foundation of growth leading to Kyphon’s eventual $4.2 billion acquisition by Medtronic. Recupero began his career at United States Surgical Corporation where he spent 10 years in various sales and sales management positions. Recupero is a graduate of the Harvard Business School General Manager Program and Kellogg Graduate School of Management Sizing and Structuring Sales Organizations program. He holds a B.A. in Communications from the State University of New York at Albany.”

Asked what he is most looking forward to, Recupero told OTW, “I am very excited to be joining SI-BONE at this inflection point with 40 clinical studies including clinically important Level I data, significant momentum on coverage decisions and committed surgeons supporting our growth in the U.S. and world-wide.”

“As I move into the new position I will work with our sales and marketing teams to leverage our industry leading outcomes data with thought leading surgeons including those I have worked with over the years at Spine-Tech, Kyphon and Baxano.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy